Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
METAVIVOR via THE FEDERAL GROUP, INC.
2026 · second_quarter · Q2
Issues relating to metastatic breast cancer, including the MetastaticBreast Cancer Access to Care Act and the Cancer Drug Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
METAVIVOR via THE FEDERAL GROUP, INC.
2026 · first_quarter · Q1
Source: Senate LDA
Issues relating to metastatic breast cancer, including the MetastaticBreast Cancer Access to Care Act and the Cancer Drug Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
METAVIVOR via THE FEDERAL GROUP, INC.
2025 · fourth_quarter · Q4
Issues relating to metastatic breast cancer, including the MetastaticBreast Cancer Access to Care Act and the Cancer Drug Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
METAVIVOR via THE FEDERAL GROUP, INC.
2025 · third_quarter · Q3
Issues relating to metastatic breast cancer, including the MetastaticBreast Cancer Access to Care Act and the Cancer Drug Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
METAVIVOR via THE FEDERAL GROUP, INC.
2025 · second_quarter · Q2
Issues relating to metastatic breast cancer, including the MetastaticBreast Cancer Access to Care Act and the Cancer Drug Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
METAVIVOR via THE FEDERAL GROUP, INC.
2025 · first_quarter · RR
Issues relating to metastatic breast cancer
Issues relating to metastatic breast cancer